Canada
· Delayed Price · Currency is CAD Ventripoint Diagnostics Statistics
Total Valuation
Ventripoint Diagnostics has a market cap or net worth of CAD 22.67 million. The enterprise value is 23.56 million.
| Market Cap | 22.67M |
| Enterprise Value | 23.56M |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ventripoint Diagnostics has 161.91 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 161.91M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | n/a |
| Float | 161.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.69 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.28
| Current Ratio | 0.28 |
| Quick Ratio | 0.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -50.89 |
Financial Efficiency
Return on equity (ROE) is -2,972.60% and return on invested capital (ROIC) is -315.68%.
| Return on Equity (ROE) | -2,972.60% |
| Return on Assets (ROA) | -136.72% |
| Return on Capital (ROIC) | -315.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.39 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 36.16 |
| Average Volume (20 Days) | 142,079 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ventripoint Diagnostics had revenue of CAD 72,067 and -5.02 million in losses. Loss per share was -0.03.
| Revenue | 72,067 |
| Gross Profit | 65,318 |
| Operating Income | -4.98M |
| Pretax Income | -5.02M |
| Net Income | -5.02M |
| EBITDA | -4.98M |
| EBIT | -4.98M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 305,615 in cash and 1.19 million in debt, giving a net cash position of -888,717 or -0.01 per share.
| Cash & Cash Equivalents | 305,615 |
| Total Debt | 1.19M |
| Net Cash | -888,717 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -2.05M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.15M |
Cash Flow
| Operating Cash Flow | -3.94M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 90.64% |
| Operating Margin | -6,915.99% |
| Pretax Margin | -6,966.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ventripoint Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | -22.84% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 7, 2015. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 7, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Ventripoint Diagnostics has an Altman Z-Score of -135.46. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -135.46 |
| Piotroski F-Score | n/a |